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Abstract 
Endocrine therapy-induced hair loss (ETIHL) associated with aromatase inhibitors and tamoxifen treatment is currently 
mostly reported but remained an unresolved therapeutic issue in patients with breast cancer (BC) since the number 
of studies regarding the management is limited in literature. Herein we investigated the possible causes of this clinical 
problem and its relation with endocrine therapies widely used for BC survivors and made some modest practical rec-
ommendations in light of the literature review in order to provide an optimal management. On the basis of literature 
findings, common causes of hair loss apart from endocrine therapies should be investigated with an initial evaluation 
workup and then should be corrected, if observed. Treatment with topical 5-alpha reductase inhibitors and sup-
plementation of Vitamin C and omega-3 fatty acids are likely appeared to be the most appropriate treatment agents 
for ETIHL without causing an adverse effect on BC prognosis. However, more prospective, randomised, placebo-
controlled studied are required in order to confirm our results and also identify the clinical effects of this problem on 
patients with BC.
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Background
Tamoxifen and Aromatase Inhibitors (AIs) currently 
hold an important place as endocrine therapy (ET) in 
adjuvant and/or metastatic setting of the patients with 
Hormone Receptor (i.e. Estrogen Receptor+ and/or Pro-
gesterone Receptor+) positive invasive or non-invasive 
breast cancer (BC) (Early Breast Cancer Trialists’ Col-
laborative Group (EBCTCG) 2005; Howell et  al. 2005). 
However, a substantial portion of the patients using 
tamoxifen therapy for many years are reported to suffer 
from the hair loss (HL) or hair thinning (Gallicchio et al. 
2013). A retrospective questioning of the patients with 
BC regarding this therapeutic issue has revealed that 
approximately 25 % of the patients receiving ET experi-
ence HL or thinning (Gallicchio et al. 2013). So that, this 
rate is almost similar to those reported for flushing and 
arthralgia related to endocrine therapy which are well-
known to impair the quality of life and more considered 
by physicians for specific additional medications (Nira-
vath 2013; Laroche et  al. 2014). Prolonged exposure to 
androgenic effects that is increased with aging in men 
leads to frontoparietal baldness defined as “male pattern 
baldness”, however, HL in women arises on the midscalp 
and/or globalscalp due to the diminished estrogen levels 
in advanced ages (Olsen 2001). Hair texture of the scalp 
consists a plenty of estrogen and androgen receptors, 
particularly frontal and parietal area (Wood and Price 
1999). An assessment of androgenetic alopecia with a 
comparison of 12 women (aged 14–33 years) and 12 men 
(aged 18–30  years) showed that frontal scalp had more 
androgen and 5-alpha reductase receptor in comparison 
to occipital scalp in both sexes. However, relative values 
were found to be much more greater in men compared 
to women (Sawaya and Price 1997). This explains the 
difference patterns of HL in men and women in normal 
circumstances. AIs widely used in BC treatment (letro-
zole, anastrozole, exemestan) and tamoxifen known as 
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selective estrogen receptor modulator are known to 
cause HL (male pattern baldness) or hair thinning in 
women (Gallicchio et  al. 2013). Rebound increased lev-
els of androgen alongside the diminished levels of estro-
gen due to AIs are supposed to decelerate and inhibit the 
proliferation of the hair follicles in the skin (Rossi et  al. 
2013). Reduced estrogenic effects due to tamoxifen ena-
bles the hair folliclesis go into the resting phase (Gateley 
and Bundred 1997). These mechanisms mentioned above 
may be the main reasons of HL caused by ET. Besides, 
one another possible mechanism may be explained with 
the theory of that tamoxifen or AIs lead to HL directly 
on growth receptors or through immunological mecha-
nisms, however, a study with respect to this issue has not 
yet been performed.
Although it is known that chemotherapy-induced HL 
during adjuvant chemotherapy is a temporary clinical 
issue, it constitutes a great concern and cosmetic prob-
lem in patients with BC. Many patients therefore tries 
to overcome this period by covering their heads with a 
wig, however, this situation may psychologically leads 
to treatment rejection or discontinuation. By contrast, 
although patients with advanced disease treated with 
chemotherapy also faced with similar HL problems, cos-
metic care in such patients generally remains in the back-
ground as they are primarily aware of the importance of 
the metastatic process along with the treatment response 
(Lemieux et al. 2008). Thus, because the endocrine ther-
apy-induced hair loss (ETIHL) negatively effects the soci-
ocultural status and quality of life, it is a major problem 
and remains a therapeutic challenge in patients with BC, 
hence should be managed by effective treatment options 
which are capable to stop the HL rather than additional 
psychological or prosthetic options.
Current recommendations for chemotherapy 
induced hair loss
Minoxidil is a vasodilator drug, it is considered a drug to 
promote hair growth (Olsen et al. 1985). So far, numer-
ous of agents and methods such as cold application to 
scalp or local minoxidil therapy have been used during 
chemotherapy period for the management of HL that 
negatively effects the quality of life among BC survivors. 
While minoxidil has been shown to provide a faster hair 
growth rather than preventing the HL in clinical trails 
(Wang et  al. 2006), despite a positive treatment effect, 
cold application to the scalp has not been considered to 
be effective and useful in this direction since it causes 
lots of complications such as infection and thrombosis 
(Trüeb 2010). Although AIs or tamoxifen-induced HL is 
a common clinical entity and problem for both oncolo-
gists and their patients and also frequently asked and 
encountered clinical issue which leads patients to seek 
for a remedy at websites (Tamoxifen and March 2016), 
it is surprising and distressing that no randomized con-
trolled studies with respect to this issue have yet been 
designed. Theoretically, the direct implementation of 
the estrogenic effective creams on the scalp tissue may 
decrease the ETIHL. However, when considering the 
AI therapy to be used for a total of 5 years, whether the 
systemic transition risk of the estrogenic therapy plays a 
negative effect on disease recurrence in patients with BC 
is still an enigma and also requires to be clarified in light 
of the randomized, placebo-controlled trials to demon-
strate the efficacy and safety of this treatment. Herein, 
we have evaluated the possible role of most recently sug-
gested nutritional supplements and 5-a reductase inhibi-
tors with considering the possible hormonal mechanisms 
in the prevention of ETIHL.
Possible treatment options for ETIHL
For the purpose of preventing the ETIHL, reducing the 
rebound androgenic effects by maintaining the anti-estro-
genic effect may theoretically act as a potential beneficial 
method for the hair follicle. To do so, combining the endo-
crine therapies (such as LHRH agonists) with mitotane and 
ketoconazole which are used to disrupt the ovarian or adre-
nal androgenic hormones synthesis may provide this effect 
(Santen and Samojlik 2013). However, some suppression 
therapies of adrenal glands functions, particularly ketocon-
azole, have various side-effects such as adrenal insufficiency 
and hepatic enzyme suppression (Boetsch et al. 2015).
In healthy adults, estrogen is known to play a key role 
in the hair development in tissue levels and also increase 
the amino acids and trace elements (such as selenium, 
cysteine) in hair texture (Zhou et al. 2012). For this rea-
son, trace elements and/or vitamin supplements may 
prevent the ETIHL. Moreover, one another important 
example to demonstrate the beneficial role of vitamins on 
hair health is that vitamin B6 is known to decrease the 
efficacy of the estrogen in hair texture or other tissues 
(Finner 2013; Hertz 1948). Today, even though the opin-
ion of that B6 supplements (topical or systemic) may be 
used to treat the baldness, this can theoretically reduce 
the estrogenic effects on the scalp, hence may not be 
effective in the management of ETIHL.
Vitamin C potentiates the estrogenic effects in vascular 
levels and also reduces the effectiveness of testosterone 
(Hwang et  al. 2000). Alongside the increased estrogenic 
activity, vitamin C also has a protective role against the 
BC (Kim et al. 2006), coronary artery disease (Hwang et al. 
2000) and osteoporosis (Sahni et al. 2009). Thus, vitamin 
C may loco regionally reduces the HL by increased estro-
genic effects along with decreased androgenic effects on 
the scalp, when locally applied with an oil-based buffer 
that enables vitamin C to pass across the hair texture.
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While the low levels of vitamin D are suggested to have 
an adverse effect on the survival of patients with BC, sup-
plementation of vitamin D deficiency is known to improve 
the survival (Mohr et al. 2014). Besides, low levels of vita-
min D in serum and/or lack of Vitamin D receptor have 
been found to be associated with HL (Rasheed et al. 2013; 
Amor et  al. 2010). However, it is still uncertain whether 
vitamin D supplementation increases the proliferation of 
hair follicles (Amor et al. 2010; Rosen et al. 2012).
Vitamin E has been shown to decrease the effectiveness 
of estrogen in the breast tissue and low levels of vitamin E 
are also reported to be associated with increased levels of 
estrogen (Chamras et al. 2005). However, according to the 
results of the SELECT study in which an increased rate of 
prostate cancer was reported, Vitamin E carried a poten-
tial androgenic and anti-estrogenic activity in patients 
receiving Vitamin E supplementation (Dunn et al. 2010).
Folic acid is also reported to have a positive effect on 
hair health (Rushton 2002), however, unfortunately, there 
are some epidemiological studies that suggest folate may 
increase the tissue levels of estrogen, indicating that high 
levels of folic acid might lead to BC (Kim 2006).
Oral supplementation of omega-3 and -6 fatty acids is 
also known to positively affect (Pardini 2006) the prog-
nosis of BC (Bartsch et  al. 1999) and many other can-
cers and also increase the apoptosis of BC cells (Sun 
et  al. 2011) in tissue cultures. Additionally, it has been 
recently shown that 6 months after the use of these fatty 
acids were found to protect and improve the hair health 
through antioxidant effects on the scalp tissue (Floc’h 
et al. 2015).
Apart from nutritional supplements, another impor-
tant point for the potential treatment of ETIHL is hor-
monal manipulation, undoubtedly. Because AIs block 
the formation of estrogen from androgens, more testos-
terone synthesis may occur from the androgens accumu-
lated behind, hence might increase the 5-alpha reductase 
enzyme activity in tissue levels, leading to much more 
dihydrotestosterone formation that is known to be the 
most potent androgenic structure in human body. There-
fore, specific and systemic treatment with anti-5-alpha 
reductase agents (such as finasteride or dutasteride) 
may preclude both HL on the scalp and male pattern 
hair growth in other parts of the body. Genuinely, the 
fact that patients with deficiency of congenital 5-alpha 
reductase enzyme activity rarely present (Herskovitz and 
Tosti 2013) with male pattern HL or that patients using a 
5-alpha reductase enzyme inhibitors have an significant 
improvement (Olsen et  al. 2006) in HL is the objective 
evidence of this situation. By contrast, given the systemic 
side effects of these agents, topical 5-alpha reductase 
enzyme inhibitors may be locally (particularly frontal-
temporal regions) or entirely applied on the scalp skin.
Rationality for safety and availability
When taking into account the aforementioned poten-
tial positive effects and risks of the treatment strategies, 
vitamin C and folic acid, providing only local use, are 
more likely to be the most potential and effective treat-
ment agents due to the fact that they have a short half-
life duration and that vitamin C is stored in the body for 
a long time, leading to increased levels in the systemic 
circulation and preventing the breast cancer recurrence. 
Moreover, vitamin C may have a protective role from 
AI-induced osteoporosis, providing a more potentiate 
effect to the current osteoporosis treatments. Because to 
positive direction of hair follicle proliferation stimulat-
ing effect of the vitamin D receptor is ligand independ-
ent, Vitamin D supplementation should not be much of a 
contribution on ETIHL. Besides, omega-3 fatty acids are 
another potential treatment agents in the prevention of 
ETIHL because of having positive effects on both breast 
tissue and hair health. Based upon these findings, when 
considering the underlying mechanism, we emphasize 
that 5-alpha reductase enzyme inhibitors (local cream or 
shampoo forms) could possibly be the most appropriate 
and potent treatment options in the treatment of ETIHL. 
It is also clear that systemic suppression methods of 
androgen synthesis may not be appropriate options due 
to systemic potential side effects (for instance; adrenal 
insufficiency)which can not be worth to take risk for cos-
metic purposes and may also lead to potential comorbidi-
ties or mortalities. Despite having no adverse effect on 
BC prognosis, vitamin E does not appear to be beneficial 
since they might provoke the male pattern HL by its pos-
sible androgenic effects.
Summary
Endocrine therapy-induced HL have remained an impor-
tant but less cared cosmetic problem in patients with 
breast cancer. When considering that one forth of the 
patients with breast cancer using endocrine therapy 
encounter with this clinical problem; rather than suggest-
ing patients anti-HL methods, it would be more benefi-
cial and effective to suggest them (before they start the 
complaining of HL problem) to be aware of that HL could 
be resolved. Today, there is no evidence based therapy 
with regard to this issue. In addition to those suggestions, 
before planning an initial endocrine therapy, several fac-
tors which may lead to HL including zinc and trace ele-
ment deficiencies, other endocrine disorders and fungal 
or bacterial infections on the scalp should be primarily 
evaluated in patients suffering ETIHL.
In conclusion, we would like to emphasise that topi-
cal 5-alpha reductase inhibitors and supplementation of 
vitamin C and omega 3 fatty acids in a non-toxic dose 
without leading to any adverse effect on the prognosis 
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of the patients with breast cancer appear to be the most 
appropriate options in the management. However, more 
prospective, placebo-controlled studies are currently 
required to prove the efficacy of these treatment methods 
in endocrine therapy induced hair loss.
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